根据12月31日提交至美国证券交易委员会的文件，Redhill Biopharma有限公司已就销售股东计划发行与出售最多6,465,559份美国存托股份（ADSS）提交相关招股说明书。
该文件披露了销售股东拟进行的股份出售安排，但未透露具体定价与发行时间表。招股说明书的提交标志着相关股份发售程序已启动，后续进展仍待监管审批与市场条件确定。
作为专注于胃肠道疾病创新疗法的生物制药企业，Redhill Biopharma此次股份发售动向引发市场关注。公司此前通过并购与自主研发不断拓展产品管线，此次资本运作可能为其后续研发提供资金支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.